nivolumab + doxorubicin + bleomycin + vinblastine + dacarbazine

Nivolumab is a human monoclonal antibody that targets the programmed cell death protein 1 (PD-1) receptor on T cells, acting as a checkpoint inhibitor to enhance the immune system's ability to identify and destroy cancer cells. In the specific context of clinical research at Memorial Sloan Kettering Cancer Center (MSKCC), nivolumab is being investigated as a front-line treatment for untreated classical Hodgkin lymphoma in combination with the standard chemotherapy regimen A(B)VD, which consists of doxorubicin, vinblastine, and dacarbazine, with or without bleomycin. This combination therapy aims to integrate the immune-modulating effects of PD-1 blockade with the direct cytotoxic activity of conventional chemotherapy to improve progression-free survival and cure rates in high-risk patients. The regimen is typically administered intravenously in 28-day cycles.

Brand names

Opdivo

Other names

nivolumab + ABVDnivolumab + AVDN-ABVDN-AVDnivolumab and A(B)VD